Works by Erba, Harry P.

Results: 37
    1
    2
    3

    A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612

    Published in:
    Leukemia & Lymphoma, 2023, v. 64, n. 2, p. 473, doi. 10.1080/10428194.2022.2148212
    By:
    • Assouline, Sarit;
    • Michaelis, Laura C.;
    • Othus, Megan;
    • Hay, Annette E.;
    • Walter, Roland B.;
    • Jacoby, Meagan A.;
    • Schroeder, Mark A.;
    • Uy, Geoffrey L.;
    • Law, Lisa Y.;
    • Cheema, Faisal;
    • Sweet, Kendra L.;
    • Asch, Adam S.;
    • Liu, Jijun;
    • Moseley, Anna B.;
    • Maher, Tracy;
    • Kingsbury, Laura L.;
    • Fang, Min;
    • Radich, Jerald;
    • Little, Richard F.;
    • Erba, Harry P.
    Publication type:
    Article
    4
    5
    6
    7
    8
    9

    Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia.

    Published in:
    American Journal of Hematology, 2018, v. 93, n. 2, p. E49, doi. 10.1002/ajh.24980
    By:
    • Walter, Roland B.;
    • Michaelis, Laura C.;
    • Othus, Megan;
    • Uy, Geoffrey L.;
    • Radich, Jerald P.;
    • Little, Richard F.;
    • Hita, Sandi;
    • Saini, Lalit;
    • Foran, James M.;
    • Gerds, Aaron T.;
    • Klepin, Heidi D.;
    • Hay, Annette E.;
    • Assouline, Sarit;
    • Lancet, Jeffrey E.;
    • Couban, Stephen;
    • Litzow, Mark R.;
    • Stone, Richard M.;
    • Erba, Harry P.
    Publication type:
    Article
    10
    11

    MDS-335: Ivosidenib (IVO) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome (R/R MDS): Updated Enrollment for the MDS Sub-Study.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S346, doi. 10.1016/S2152-2650(21)01805-X
    By:
    • DiNardo, Courtney D.;
    • Foran, James M.;
    • Watts, Justin M.;
    • Stein, Eytan M.;
    • de Botton, Stéphane;
    • Fathi, Amir T.;
    • Prince, Gabrielle T.;
    • Stein, Anthony S.;
    • Stone, Richard M.;
    • Patel, Prapti A.;
    • Roboz, Gail J.;
    • Arellano, Martha L.;
    • Erba, Harry P.;
    • Pigneux, Arnaud;
    • Stuart, Robert K.;
    • Thomas, Xavier;
    • Uy, Geoffrey L.;
    • Lemieux, Ian R.;
    • Zhang, Vickie;
    • Kapsalis, Stephanie M.
    Publication type:
    Article
    12

    Poster: MDS-335: Ivosidenib (IVO) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome (R/R MDS): Updated Enrollment for the MDS Sub-Study.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S230, doi. 10.1016/S2152-2650(21)01451-8
    By:
    • DiNardo, Courtney D.;
    • Foran, James M.;
    • Watts, Justin M.;
    • Stein, Eytan M.;
    • De Botton, Stéphane;
    • Fathi, Amir T.;
    • Prince, Gabrielle T.;
    • Stein, Anthony S.;
    • Stone, Richard M.;
    • Patel, Prapti A.;
    • Roboz, Gail J.;
    • Arellano, Martha L.;
    • Erba, Harry P.;
    • Pigneux, Arnaud;
    • Stuart, Robert K.;
    • Thomas, Xavier;
    • Uy, Geoffrey L.;
    • Lemieux, Ian R.;
    • Zhang, Vickie;
    • Kapsalis, Stephanie M.
    Publication type:
    Article
    13
    14

    Ivosidenib (IVO; AG-120) in IDH1-Mutant Newly-Diagnosed Acute Myeloid Leukemia (ND AML): Updated Results from a Phase 1 Study.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S220, doi. 10.1016/j.clml.2019.07.094
    By:
    • DiNardo, Courtney D.;
    • Roboz, Gail J.;
    • Stein, Eytan M.;
    • de Botton, Stéphane;
    • Mims, Alice S.;
    • Prince, Gabrielle T.;
    • Altman, Jessica K.;
    • Arellano, Martha L.;
    • Donnellan, Will;
    • Erba, Harry P.;
    • Mannis, Gabriel N.;
    • Pollyea, Daniel A.;
    • Stein, Anthony S.;
    • Uy, Geoffrey L.;
    • Watts, Justin M.;
    • Fathi, Amir T.;
    • Kantarjian, Hagop M.;
    • Tallman, Martin S.;
    • Choe, Sung;
    • Dai, David
    Publication type:
    Article
    15

    Ivosidenib (AG-120) in Mutant IDH1 Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase 1 Study.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S204, doi. 10.1016/j.clml.2018.07.057
    By:
    • DiNardo, Courtney D.;
    • Stein, Eytan M.;
    • de Botton, Stéphane;
    • Roboz, Gail J.;
    • Altman, Jessica K.;
    • Mims, Alice S.;
    • Swords, Ronan;
    • Collins, Robert H.;
    • Mannis, Gabriel N.;
    • Pollyea, Daniel A.;
    • Donnellan, Will;
    • Fathi, Amir T.;
    • Pigneux, Arnaud;
    • Erba, Harry P.;
    • Prince, Gabrielle T.;
    • Stein, Anthony S.;
    • Uy, Geoffrey L.;
    • Foran, James M.;
    • Traer, Elie;
    • Stuart, Robert K.
    Publication type:
    Article
    16
    17
    18
    19
    20

    Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patients.

    Published in:
    Biomarker Research, 2023, v. 11, n. 1, p. 1, doi. 10.1186/s40364-023-00461-0
    By:
    • Pogosova-Agadjanyan, Era L.;
    • Hua, Xing;
    • Othus, Megan;
    • Appelbaum, Frederick R.;
    • Chauncey, Thomas R.;
    • Erba, Harry P.;
    • Fitzgibbon, Matthew P.;
    • Jenkins, Isaac C.;
    • Fang, Min;
    • Lee, Stanley C.;
    • Moseley, Anna;
    • Naru, Jasmine;
    • Radich, Jerald P.;
    • Smith, Jenny L.;
    • Willborg, Brooke E.;
    • Willman, Cheryl L.;
    • Wu, Feinan;
    • Meshinchi, Soheil;
    • Stirewalt, Derek L.
    Publication type:
    Article
    21

    AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report.

    Published in:
    Biomarker Research, 2020, v. 8, n. 1, p. 1, doi. 10.1186/s40364-020-00208-1
    By:
    • Pogosova-Agadjanyan, Era L.;
    • Moseley, Anna;
    • Othus, Megan;
    • Appelbaum, Frederick R.;
    • Chauncey, Thomas R.;
    • Chen, I-Ming L.;
    • Erba, Harry P.;
    • Godwin, John E.;
    • Jenkins, Isaac C.;
    • Fang, Min;
    • Huynh, Mike;
    • Kopecky, Kenneth J.;
    • List, Alan F.;
    • Naru, Jasmine;
    • Radich, Jerald P.;
    • Stevens, Emily;
    • Willborg, Brooke E.;
    • Willman, Cheryl L.;
    • Wood, Brent L.;
    • Zhang, Qing
    Publication type:
    Article
    22
    23
    24
    25

    Real‐world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower‐risk myelodysplastic syndromes.

    Published in:
    International Journal of Laboratory Hematology, 2021, v. 43, n. 3, p. 426, doi. 10.1111/ijlh.13400
    By:
    • Patel, Jay L.;
    • Abedi, Mehrdad;
    • Cogle, Christopher R.;
    • Erba, Harry P.;
    • Foucar, Kathryn;
    • Garcia‐Manero, Guillermo;
    • Grinblatt, David L.;
    • Komrokji, Rami S.;
    • Kurtin, Sandra E.;
    • Maciejewski, Jaroslaw P.;
    • Pollyea, Daniel A.;
    • Revicki, Dennis A.;
    • Roboz, Gail J.;
    • Savona, Michael R.;
    • Scott, Bart L.;
    • Sekeres, Mikkael A.;
    • Steensma, David P.;
    • Thompson, Michael A.;
    • Dawn Flick, Elizabeth;
    • Kiselev, Pavel
    Publication type:
    Article
    26

    Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.

    Published in:
    British Journal of Haematology, 2016, v. 172, n. 3, p. 384, doi. 10.1111/bjh.13832
    By:
    • Prebet, Thomas;
    • Sun, Zhuoxin;
    • Ketterling, Rhett P.;
    • Zeidan, Amer;
    • Greenberg, Peter;
    • Herman, James;
    • Juckett, Mark;
    • Smith, Mitchell R.;
    • Malick, Lisa;
    • Paietta, Elisabeth;
    • Czader, Magdalena;
    • Figueroa, Maria;
    • Gabrilove, Janice;
    • Erba, Harry P.;
    • Tallman, Martin S.;
    • Litzow, Mark;
    • Gore, Steven D.
    Publication type:
    Article
    27

    Pevonedistat ( MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.

    Published in:
    British Journal of Haematology, 2015, v. 169, n. 4, p. 534, doi. 10.1111/bjh.13323
    By:
    • Swords, Ronan T.;
    • Erba, Harry P.;
    • DeAngelo, Daniel J.;
    • Bixby, Dale L.;
    • Altman, Jessica K.;
    • Maris, Michael;
    • Hua, Zhaowei;
    • Blakemore, Stephen J.;
    • Faessel, Hélène;
    • Sedarati, Farhad;
    • Dezube, Bruce J.;
    • Giles, Francis J.;
    • Medeiros, Bruno C.
    Publication type:
    Article
    28

    Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS.

    Published in:
    British Journal of Haematology, 2014, v. 167, n. 1, p. 62, doi. 10.1111/bjh.13008
    By:
    • Zeidan, Amer M.;
    • Lee, Ju‐Whei;
    • Prebet, Thomas;
    • Greenberg, Peter;
    • Sun, Zhuoxin;
    • Juckett, Mark;
    • Smith, Mitchell R.;
    • Paietta, Elisabeth;
    • Gabrilove, Janice;
    • Erba, Harry P.;
    • Katterling, Rhett P.;
    • Tallman, Martin S.;
    • Gore, Steven D.
    Publication type:
    Article
    29

    Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes.

    Published in:
    British Journal of Haematology, 2014, v. 166, n. 3, p. 352, doi. 10.1111/bjh.12884
    By:
    • Zeidan, Amer M.;
    • Lee, Ju‐Whei;
    • Prebet, Thomas;
    • Greenberg, Peter;
    • Sun, Zhuoxin;
    • Juckett, Mark;
    • Smith, Mitchell R.;
    • Paietta, Elisabeth;
    • Gabrilove, Janice;
    • Erba, Harry P.;
    • Tallman, Martin S.;
    • Gore, Steven D.
    Publication type:
    Article
    30

    Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia.

    Published in:
    British Journal of Haematology, 2010, v. 148, n. 1, p. 48, doi. 10.1111/j.1365-2141.2009.07919.x
    By:
    • Chauncey, Thomas R.;
    • Gundacker, Holly;
    • Shadman, Mazyar;
    • List, Alan F.;
    • Dakhil, Shaker R.;
    • Erba, Harry P.;
    • Slovak, Marilyn L.;
    • I-Ming Chen;
    • Willman, Cheryl L.;
    • Kopecky, Kenneth J.;
    • Appelbaum, Frederick R.
    Publication type:
    Article
    31
    32
    33

    Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States.

    Published in:
    2017
    By:
    • Pine, Alexander B.;
    • Lee, Eun‐Ju;
    • Sekeres, Mikkael;
    • Steensma, David P.;
    • Zelterman, Daniel;
    • Prebet, Thomas;
    • DeZern, Amy;
    • Komrokji, Rami;
    • Litzow, Mark;
    • Luger, Selina;
    • Stone, Richard;
    • Erba, Harry P.;
    • Garcia‐Manero, Guillermo;
    • Lee, Alfred I.;
    • Podoltsev, Nikolai A.;
    • Barbarotta, Lisa;
    • Kasberg, Stephanie;
    • Hendrickson, Jeanne E.;
    • Gore, Steven D.;
    • Zeidan, Amer M.
    Publication type:
    journal article
    34
    35

    Proteogenomic characterization of highly enriched viable leukemic blasts in acute myeloid leukemia: A SWOG report.

    Published in:
    EJHaem, 2024, v. 5, n. 6, p. 1243, doi. 10.1002/jha2.1041
    By:
    • Naru, Jasmine;
    • Othus, Megan;
    • Lin, ChenWei;
    • Biernacki, Melinda A.;
    • Bleakley, Marie;
    • Chauncey, Thomas R.;
    • Erba, Harry P.;
    • Fang, Min;
    • Fitzgibbon, Matthew P.;
    • Gafken, Phillip R.;
    • Ivey, Richard G.;
    • Kennedy, Jacob J.;
    • Lorentzen, Travis D.;
    • Meshinchi, Soheil;
    • Moseley, Anna;
    • Pogosova‐Agadjanyan, Era L.;
    • Liu, Vivian M.;
    • Radich, Jerald P.;
    • Voytovich, Uliana J.;
    • Wang, Pei
    Publication type:
    Article
    36
    37